Enlivex Therapeutics Ltd. (ENLV:NASDAQ) closed at $1.37 on November 9, 2026, up 7.87% on the day. The stock trades 99.7% below its 52-week high of $434.40 and 12.3% above its 52-week low of $1.22. Over the past year, it lost 90.9%. Enlivex Therapeutics Ltd. is part of the Health Care sector (Major Pharmaceuticals).
In 251 trading sessions since November 7, 2025, ENLV closed higher on 89 days (35%). Its best day was May 27, 2026 (+14.33%) and its worst was July 28, 2026 (-47.42%). The stock moved 10% or more in a single session 23 times. It opened at least 5% above the previous day's high 5 times.
Bioblast Pharma Ltd is an Israel-based development-stage biopharmaceutical company. The firm is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations.
Find more stocks like ENLV with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.